The company is using safe probiotics as antigen presenters to develop an innovative mucosal vaccines which can be administered needle-free via the nose or mouth.
The lead product is preparing for a Phase I trial in September, with hopes to potentially start Phase II next year. Notably, the company got a €3.7M funding from the Wellcome Trust earlier this year, which is a great recognition of the potential of the platform.
So I asked Tom my more pressing questions to better understand their technology…
Feature Image Credit: Philip Hemme interviewing Tom Johnston at BioTrinity 2016
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.